Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524336 | 0.83 | FFAR1 (0.41) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| Hydrochloric Acid SCHEMBL10762171 | 0.81 | FFAR1 (0.40) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| Hydrochloric Acid SCHEMBL10765310 | 0.81 | FFAR1 (0.40) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL8110277 | 0.76 | GPR84 (0.42) | FFAR1 | |
| SCHEMBL10762165 | 0.76 | FFAR1 (0.36) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL5528347 | 0.75 | CYP4F2 (0.36) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL11150219 | 0.74 | CA2 (0.41) | FFAR1 | |
| SCHEMBL5528316 | 0.74 | CYP4F2 (0.38) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL10762159 | 0.68 | FFAR1 (0.37) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL11048262 | 0.68 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1572189-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004045596-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-4711896-A | ANTIDIABETIC, ANTILIPEMIC AGENTS | EPIS S.A. (CH) | 1987-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | CYP4F2 1467/4885CYP4A11 3892/4885FFAR1 144/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | CYP4F2 3452/4885CYP4A11 1902/4885FFAR1 1371/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | CYP4F2 387/4885CYP4A11 56/4885FFAR1 265/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | CYP4F2 137/4885CYP4A11 236/4885FFAR1 449/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | CYP4F2 535/4885CYP4A11 325/4885FFAR1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.